Fulltext

Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study

Bonaventura K 1 , Schwefer M 2 , Yusof AKM 3 , Waliszewski M 4 , Krackhardt F 5 , Steen P 6 Show all authors , Ocaranza R 7 , Zuhdi AS 8 , Bang LH 9 , Graf K 10 , Böck U 11 , Chin K 12

Affiliations 

  • 1 Klinikum Ernst Von Bergmann, Potsdam, Germany. Klaus.Bonaventura@klinikumevb.de
  • 2 Elblandklinikum Riesa, Riesa, Germany
  • 3 The National Heart Institute of Malaysia, Kuala Lumpur, Malaysia
  • 4 Medical Scientific Affairs, B. Braun Melsungen AG, Berlin, Germany
  • 5 Department of Cardiology and Internal Medicine, Charité - Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany
  • 6 Klinikum Ernst Von Bergmann, Potsdam, Germany
  • 7 Hospital Universitario Lucus Augusti, Lugo, Spain
  • 8 Pusat Perubatan Universiti Malaya, Kuala Lumpur, Malaysia
  • 9 Hospital Queen Elizabeth II, Kota Kinabalu, Sabah, Malaysia
  • 10 Jüdisches Krankenhaus Berlin, Berlin, Germany
  • 11 Marien-Hospital Marl, Marl, Germany
  • 12 Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Adv Ther, 2020 05;37(5):2210-2223.
PMID: 32274746 DOI: 10.1007/s12325-020-01320-2

Abstract

INTRODUCTION: Scoring balloon angioplasty (SBA) for lumen gain prior to stent implantations or drug-coated balloon angioplasty (DCB) is considered an essential interventional tool for lesion preparation. Recent evidence indicates that SBA may play a pivotal role in enhancing the angiographic and clinical outcomes of DCB angioplasty.

METHODS: We studied the systematic use of SBA with a low profile, non-slip element device prior to DCB angioplasty in an unselected, non-randomized patient population. This prospective, all-comers study enrolled patients with de novo lesions as well as in-stent restenotic lesions in bare metal stents (BMS-ISR) and drug-eluting stents (DES-ISR). The primary endpoint was the target lesion failure (TLF) rate at 9 months (ClinicalTrials.gov Identifier NCT02554292).

RESULTS: A total of 481 patients (496 lesions) were recruited to treat de novo lesions (78.4%, 377), BMS-ISR (4.0%, 19), and DES-ISR (17.6%, 85). Overall risk factors were acute coronary syndrome (ACS, 20.6%, 99), diabetes mellitus (46.8%, 225), and atrial fibrillation (8.5%, 41). Average lesion lengths were 16.7 ± 10.4 mm in the de novo group, and 20.1 ± 8.9 mm (BMS-ISR) and 16.2 ± 9.8 mm (DES-ISR) in the ISR groups. Scoring balloon diameters were 2.43 ± 0.41 mm (de novo), 2.71 ± 0.31 mm (BMS-ISR), and 2.92 ± 0.42 mm (DES-ISR) whereas DCB diameters were 2.60 ± 0.39 mm (de novo), 3.00 ± 0.35 mm (BMS-ISR), and 3.10 ± 0.43 mm (DES-ISR), respectively. The overall accumulated TLF rate of 3.0% (14/463) was driven by significantly higher target lesion revascularization rates in the BMS-ISR (5.3%, 1/19) and the DES-ISR group (6.0%, 5/84). In de novo lesions, the TLF rate was 1.1% (4/360) without differences between calcified and non-calcified lesions (p = 0.158) and small vs. large reference vessel diameters with a cutoff value of 3.0 mm (p = 0.901).

CONCLUSIONS: The routine use of a non-slip element scoring balloon catheter to prepare lesions suitable for drug-coated balloon angioplasty is associated with high procedural success rates and low TLF rates in de novo lesions.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications